Talk:Baloxavir marboxil

From WikiProjectMed
Jump to navigation Jump to search

Plagiarism moved here, for re-use as blockquote or paraphrase

This blockquote was moved from the main article because it did not appear there as a quote; rather, the text of the FDA website was used, verbatim, without presenting it as a quote, violating standards regarding plagiarism (see WP:Plagiarism and other descriptions of academic expectations):

Trial 1 enrolled adult patients 20 to 64 years old who had symptoms of flu for no more than 48 hours.[1] Patients were assigned to receive either a single dose of baloxavir marboxil or placebo by mouth.[1] Neither the patients nor the health care providers knew which treatment was being given until after the trial was completed.[1] The benefit of baloxavir marboxil was assessed based on the time patients reported all seven symptoms (cough, sore throat, nasal congestion, headache, fever, muscle pain, and tiredness) gone or mild for at least 21.5 hours, comparing the baloxavir marboxil and placebo groups.[1]

Trial 2 enrolled adult and adolescent patients 12 to 64 years old who had symptoms of flu for not more than 48 hours.[1] Adult patients were assigned to receive either baloxavir marboxil on Day 1 followed by placebo on Days 2 – 5, placebo as a twice daily dose by mouth for 5 days, or oseltamivir (a medication used to treat and prevent influenza) by mouth twice a day for 5 days.[1] Neither the patients nor the health care providers knew which treatment was being given until after the trial was completed.[1] The benefit of baloxavir marboxil was assessed based on the time patients reported all seven symptoms (cough, sore throat, nasal congestion, headache, fever, muscle pain, and tiredness) gone or mild for at least 21.5 hours, comparing the baloxavir marboxil and placebo groups.[1]

  1. ^ a b c d e f g h Cite error: The named reference FDA Snapshot was invoked but never defined (see the help page).

Here is the material appearing at the FDA website, and the fact that it was not paraphrased as required, is clear:

Trial 1 enrolled adult patients 20 to 64 years old who had symptoms of flu for no more than 48 hours. Patients were assigned to receive either a single dose of XOFLUZA or placebo by mouth. Neither the patients nor the health care providers knew which treatment was being given until after the trial was completed. The benefit of XOFLUZA was assessed based on the time patients reported all seven symptoms (cough, sore throat, nasal congestion, headache, fever, muscle pain, and tiredness) gone or mild for at least 21.5 hours, comparing the XOFLUZA and placebo groups.

Trial 2 enrolled adult and adolescent patients 12 to 64 years old who had symptoms of flu for not more than 48 hours. Adult patients were assigned to receive either XOFLUZA on Day 1 followed by placebo on Days 2 – 5, placebo as a twice daily dose by mouth for 5 days, or oseltamivir (a medication used to treat and prevent influenza) by mouth twice a day for 5 days. Neither the patients nor the health care providers knew which treatment was being given until after the trial was completed. The benefit of XOFLUZA was assessed based on the time patients reported all seven symptoms (cough, sore throat, nasal congestion, headache, fever, muscle pain, and tiredness) gone or mild for at least 21.5 hours, comparing the XOFLUZA and placebo groups.

As a former academic and regular editor, I will again simply say that even if content is in the public domain, it is not acceptable to cut and paste it into another work, with text unaltered (quoting it), without indication that it is being quoted—i.e., with the text being transmitted without alteration from the original. This is true, even if markup is added to the citation to indicate public domain content use, and it is true even if each plagiarised sentence is followed by an inline citation. The text must be made our own; the text of others cannot be used, verbatim, without quotation marks.

The editor cutting and pasting this in was contacted via their Talk page, and @Doc James: was notified. One sentence of the original edit was paraphrased and integrated, so that the citation introduced could be retained. Otherwise, the bulk of that edit's cut and paste material is was moved above, until it can be used correctly, through paraphrasing or blockquoting. If blockquoting, the trade name, XOFLUZA, has to be returned, but the JAN/USAN/INN name, baloxavir marboxil, can be added in square brackets ([ ]), which properly indicates an editorial addition to the quote. 2601:246:C700:19D:A893:D336:57FE:E91C (talk) 16:50, 8 January 2020 (UTC)[reply]

Incorrect article link in “Resistance” section

The “Resistance” section under “Medical Uses” contains a link from the words, “acquired resistance,” to the Wikipedia article entitled, “Adaptive Immune System.” This article primarily gives information on how vertebrates form immunity to new infection threats, NOT how a virus might gain resistance to an antiviral medication. Please change the link to a relevant article or deactivate it. Thanks. Veracityquest (talk) 20:20, 18 June 2022 (UTC)[reply]

Good catch. I switched the link to Resistance mutation (virology). I believe that is an appropriate article. MartinezMD (talk) 20:46, 18 June 2022 (UTC)[reply]
Excellent, thanks, that was a fast response. Veracityquest (talk) 21:11, 18 June 2022 (UTC)[reply]
You're welcome. MartinezMD (talk) 22:24, 18 June 2022 (UTC)[reply]
Retrieved from "https://mdwiki.org/wiki/Talk:Baloxavir_marboxil"